Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim A Papp

Showing results (31-40 of 219) with videos related to

Pageof 22
Sort By:
The Journal of Dermatology|November 8, 2021
Real-world, long-term treatment patterns of commonly used biologics in Canadian patients with moderate-to-severe chronic plaque psoriasisMelinda J Gooderham, Charles Lynde, Irina Turchin, et al.
Dermatology and Therapy|May 21, 2021
Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive ModelKim A Papp, Ahmed M Soliman, Nicolae Done, et al.
Dermatologic Therapy|August 21, 2021
Emerging paradigm shift toward proactive topical treatment of psoriasis: A narrative reviewKim A Papp, Gurbir Dhadwal, Melinda Gooderham, et al.
Health and Quality of Life Outcomes|May 14, 2013
Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled studyVibeke Strand, David Fiorentino, ChiaChi Hu, et al.
Dermatology and Therapy|January 29, 2021
Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension TrialKim A Papp, Saskia de Vente, Jiewei Zeng, et al.
Journal of Cutaneous Medicine and Surgery|November 16, 2018
Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section II: Tools for Assessing the Severity of Atopic DermatitisMelinda J Gooderham, Robert Bissonnette, Parbeer Grewal, et al.
Journal of Drugs in Dermatology : JDD|March 17, 2017
Evaluation of the Physician Global Assessment and Body Surface Area Composite Tool for Assessing Psoriasis Response to Apremilast Therapy: Results from ESTEEM 1 and ESTEEM 2Kristina C Duffin, Kim A Papp, Jerry Bagel, et al.
Pediatrics|December 20, 2005
Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 yearsCarle Paul, Michael Cork, Ana B Rossi, et al.
International Journal of Dermatology|December 15, 2010
A Canadian online survey to evaluate awareness and treatment satisfaction in individuals with moderate to severe plaque psoriasisYves Poulin, Kim A Papp, Norman R Wasel, et al.
Dermatology and Therapy|August 2, 2021
Long-Term Proactive Treatment of Plaque Psoriasis with Calcipotriene/Betamethasone Dipropionate Foam Prolongs Remission and Reduces Relapses Irrespective of Patient Baseline CharacteristicsMark G Lebwohl, Kim A Papp, Marie Holst Mørch, et al.
Pageof 22

Showing results (31-40 of 219) with videos related to

Sort By:
Pageof 22
The Journal of Dermatology|November 8, 2021
Real-world, long-term treatment patterns of commonly used biologics in Canadian patients with moderate-to-severe chronic plaque psoriasisMelinda J Gooderham, Charles Lynde, Irina Turchin, et al.
Dermatology and Therapy|May 21, 2021
Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive ModelKim A Papp, Ahmed M Soliman, Nicolae Done, et al.
Dermatologic Therapy|August 21, 2021
Emerging paradigm shift toward proactive topical treatment of psoriasis: A narrative reviewKim A Papp, Gurbir Dhadwal, Melinda Gooderham, et al.
Health and Quality of Life Outcomes|May 14, 2013
Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled studyVibeke Strand, David Fiorentino, ChiaChi Hu, et al.
Dermatology and Therapy|January 29, 2021
Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension TrialKim A Papp, Saskia de Vente, Jiewei Zeng, et al.
Journal of Cutaneous Medicine and Surgery|November 16, 2018
Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section II: Tools for Assessing the Severity of Atopic DermatitisMelinda J Gooderham, Robert Bissonnette, Parbeer Grewal, et al.
Journal of Drugs in Dermatology : JDD|March 17, 2017
Evaluation of the Physician Global Assessment and Body Surface Area Composite Tool for Assessing Psoriasis Response to Apremilast Therapy: Results from ESTEEM 1 and ESTEEM 2Kristina C Duffin, Kim A Papp, Jerry Bagel, et al.
Pediatrics|December 20, 2005
Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 yearsCarle Paul, Michael Cork, Ana B Rossi, et al.
International Journal of Dermatology|December 15, 2010
A Canadian online survey to evaluate awareness and treatment satisfaction in individuals with moderate to severe plaque psoriasisYves Poulin, Kim A Papp, Norman R Wasel, et al.
Dermatology and Therapy|August 2, 2021
Long-Term Proactive Treatment of Plaque Psoriasis with Calcipotriene/Betamethasone Dipropionate Foam Prolongs Remission and Reduces Relapses Irrespective of Patient Baseline CharacteristicsMark G Lebwohl, Kim A Papp, Marie Holst Mørch, et al.
Pageof 22